Verastem (VSTM) Cash from Financing Activities (2011 - 2026)
Verastem (VSTM) posted quarterly Cash from Financing Activities of $28.7 million for Q1 2026, down 57.45% year-over-year from $67.4 million in Q1 2025, and down 70.9% quarter-over-quarter from $98.6 million in Q4 2025.
Analysis
Verastem (VSTM) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Verastem's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $28.7 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 57.45% year-over-year to $28.7 million; the TTM figure through Mar 2026 stood at $224.6 million (up 85.04% YoY), while the FY2025 annual figure was $263.3 million, up 380.64% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $28.7 million, down from $98.6 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $98.6 million in Q4 2025, with the low at -$891000.0 in Q3 2023.
- The 5-year median for Cash from Financing Activities is $25.5 million (2022), against an average of $33.3 million.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities sank 103.48% in 2023, then jumped 19708.89% in 2025.
- Verastem's Cash from Financing Activities stood at $25.6 million in 2022, then tumbled by 101.74% to -$446000.0 in 2023, then jumped by 266.37% to $742000.0 in 2024, then surged by 13186.12% to $98.6 million in 2025, then sank by 70.9% to $28.7 million in 2026.
- Business Quant data shows VSTM's Cash from Financing Activities at $28.7 million in Q1 2026, $98.6 million in Q4 2025, and $17.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn | -1.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.54 Mn |
| Mar 31, 2026 | 28.69 Mn |
| Dec 31, 2025 | 98.58 Mn |
| Sep 30, 2025 | 17.88 Mn |
| Jun 30, 2025 | 79.42 Mn |
| Mar 31, 2025 | 67.43 Mn |
| Dec 31, 2024 | 742,000.00 |
| Sep 30, 2024 | 53.60 Mn |
| Jun 30, 2024 | -405,000.00 |
| Mar 31, 2024 | 846,000.00 |
| Dec 31, 2023 | -446,000.00 |
| Sep 30, 2023 | -891,000.00 |
| Jun 30, 2023 | 91.48 Mn |
| Mar 31, 2023 | 44.05 Mn |
| Sep 30, 2022 | 25.62 Mn |
| Jun 30, 2022 | 708,000.00 |
| Mar 31, 2022 | 25.45 Mn |
| Dec 31, 2021 | 6.81 Mn |
| Sep 30, 2021 | 169,000.00 |
| Jun 30, 2021 | 489,000.00 |